Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SX-682 and Nivolumab as Maintenance Therapy in Metastatic Pancreatic Ductal Adenocarcinoma
NCT04477343Phase 1Active, not recruiting
- Sponsor
- University of Rochester
- Start
- Nov 2020
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SX-682 in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Rochester. Primary endpoint: Maximum tolerable dose at 6 months. Started Nov 2020; status: active, not recruiting.
02
Drugs
SX-682
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04477343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04477343.